Phase 4 N=18 HCV-HIV Co-infected Patient Cohort in Thailand
Hepatitis C Infection · HIV
Primary: Number of Participants With Sustained Virological Response 6 Months After Treatment Discontinuation — 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=80 A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir
Hepatitis C Viral · Chronic Kidney Disease stage3
Primary: Change of Serum Endostatin Level (ng/mL) From Baseline to 3 Months — 156; 176 ng/mL
Phase 4 N=31 QVA Mechanistic Efficacy Study (Receptor Effects, Etc)
Chronic Obstructive Pulmonary Disease
Primary: Global Ventilated Lung Volume — 61.73; 56.73 Percentage of total lung volume — p=0.0254
Phase 4 N=251 IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients
ESRD · Diabetes · CAPD
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
Phase 4 N=134 Adherence in Topical Treatment of Psoriasis
Adherence
Primary: Percentage of Adherent Participants — 65; 38 percentage of participants — p==0.004
Phase 4 N=60 Geriatric Ketamine for Pain Management Study
Pain
Primary: Reduction of Pain Score at 30 Minutes — 4.4; 4.2 score on a scale
Phase 4 N=69 Long Term Effectiveness of Trigger Finger Injections With Triamcinolone vs. Dexamethasone
Trigger Finger Disorder
Primary: Number of Participants With no Symptoms of Trigger Finger — 28; 9 Participants
Phase 4 N=351 Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis
Type 2 Diabetes Mellitus · Coronary Atherosclerosis
Primary: Prevalence of Occult Myocardial Scar on Delayed-enhanced MRI in Asymptomatic Patients With Type 2 Diabetes Mellitus — 23 Participants
Phase 4 N=275 Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients
Renal Transplant Rejection
Primary: Incidence of Acute Cellular Rejection — 7; 31 Participants
Phase 4 N=110 A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.
Type 2 Diabetes Mellitus
Primary: Percentage of Participants With Adverse Events(AEs) and Serious Adverse Event(SAEs) — 52.9; 3.8 percentage of participants
Phase 4 N=178 Sigma CR150 Versus Sigma CR Knee RCT
Osteoarthritis
Primary: Percentage of Knees Who Survived at 2 Years Post-operative — 100; 100 Percentage of Knees remaining
Phase 4 N=130 Evaluation of Ureteral Patency in the Post-indigo Carmine Era
Ureteral Patency
Primary: Visual Analog Scale (VAS) — 48; 20; 0; 28 score on a scale
Phase 4 N=106 Veteran Stress and Learning Study
Stress Disorders, Posttraumatic
Primary: Proportion of Maximum Skin Conductance Response (SCR) in Microsiemens (µS) — .0325522; .0245775; -.0181339; .1233174 proportion of max SCR (µS) — p==.66
Phase 4 N=42 Effect of Deep Neuromuscular Block (NMB), Inhalation or TIVA on Pneumoperitoneum.
Muscle Relaxation
Primary: Effect of Anesthetics on the Pressure at Zero Volume (PV0) Measured During Insufflation of the Abdomen — 5.7; 8.29; 6.58 mmHg
Phase 4 N=55 Clinical Evaluation of Two Marketed Artificial Tears in Non-contact Lens Wearing Patients
Visual Acuity
Primary: Ocular Comfort — 81.96; 82.49 Units on a scale